Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts

医学 前瞻性队列研究 内科学 风险评估 队列研究 梅德林 队列 风险因素 急诊医学 重症监护医学 疾病 糖尿病 流行病学
作者
Zhenyu Huo,Yijun Chen,Yating Huang,Zhirong Yang,Yujun Long,Qian Zhang,Shuohua Chen,Guodong Wang,Shengtao Zhu,Dianjianyi Sun,Canqing Yu,Jun Lv,Liming Li,Ming‐Hua Zheng,Shouling Wu,Yuanjie Pang,Shanshan Wu
出处
期刊:Gut [BMJ]
卷期号:75 (4): 772-785 被引量:70
标识
DOI:10.1136/gutjnl-2025-336127
摘要

BACKGROUND: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at increased risk of both hepatic and extrahepatic adverse outcomes. However, the evidence regarding lean MASLD and its prognosis remains controversial. OBJECTIVE: To comprehensively investigate the long-term prognosis of lean patients with MASLD versus non-lean MASLD in Western and Asian populations. DESIGN: This prospective multicohort study included 153 192 patients with MASLD from UK Biobank (UKB), 29 700 from Kailuan cohort and 3329 from China Kadoorie Biobank (CKB). Lean MASLD was defined as body mass index (BMI)<23 kg/m² in Kailuan and CKB and <25 kg/m² in UKB. Primary endpoints were liver-related events (LREs), all-cause mortality, liver-related mortality (LRM), cardiovascular disease (CVD) mortality, CVD, hepatocellular carcinoma (HCC) and extrahepatic cancer. RESULTS: Overall, 181 191 non-lean and 5030 lean patients with MASLD were included. During a median of 14.2-year follow-up (median 14.1, 14.8 and 13.4 years in UKB, Kailuan and CKB), 2501 incident LREs, 22 482 all-cause deaths, 28 722 incident CVD cases, 326 HCC and 25 258 extrahepatic cancer cases were identified, with 375 LRM and 4511 CVD deaths. Pooled analysis of three cohorts showed lean MASLD had higher risks of LREs (HR=2.14; 95% CI 1.27 to 3.62), all-cause mortality (HR=1.26; 95% CI 1.14 to 1.39), LRM (HR=2.31; 95% CI 1.54 to 3.46) and CVD mortality (HR=1.22; 95% CI 1.05 to 1.41). By contrast, lean MASLD exhibited comparable HCC risk (HR=1.76; 95% CI 0.84 to 3.71) and extrahepatic cancer risk (HR=1.14; 95% CI 0.88 to 1.48), but reduced CVD risk (HR=0.89; 95% CI 0.83 to 0.95) versus non-lean MASLD. CONCLUSION: Lean patients with MASLD have worse liver outcomes and greater risk of all-cause mortality, but similar risk of HCC and extrahepatic cancer, and lower CVD risk.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
高高行云发布了新的文献求助10
1秒前
补丁完成签到,获得积分10
1秒前
sun发布了新的文献求助10
1秒前
团团团子完成签到 ,获得积分10
1秒前
2秒前
小王小王发布了新的文献求助10
3秒前
慕青的应助被Nooooo采纳,获得10
3秒前
doing完成签到,获得积分10
3秒前
盛盛完成签到,获得积分10
3秒前
4秒前
4秒前
Layman发布了新的文献求助10
5秒前
李健的粉丝团团长的应助被hh采纳,获得10
5秒前
第七兵团司令完成签到,获得积分10
5秒前
6秒前
7秒前
8秒前
小蘑菇的应助被实验一次成功采纳,获得10
8秒前
9秒前
LiLi完成签到,获得积分10
9秒前
晨曦发布了新的文献求助10
9秒前
Ambition发布了新的文献求助20
9秒前
sherlock完成签到,获得积分10
10秒前
10秒前
CodeCraft的应助被Layman采纳,获得10
10秒前
11秒前
GBY发布了新的文献求助10
11秒前
共享精神的应助被微风无起采纳,获得10
11秒前
11秒前
12秒前
timesever完成签到,获得积分10
12秒前
12秒前
throb发布了新的文献求助10
12秒前
13秒前
14秒前
蓝天发布了新的文献求助10
15秒前
16秒前
巧克力发布了新的文献求助10
16秒前
LAN完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177802
求助须知:如何正确求助?哪些是违规求助? 9568632
关于积分的说明 21799933
捐赠科研通 7772424
什么是DOI,文献DOI怎么找? 3432505
关于科研通互助平台的介绍 2556698
邀请新用户注册赠送积分活动 2478055